Biora Therapeutics, Inc. BIORQ
0.00
(0.22)
(100.00%)
as of 24 Sep
- Market cap
- $2.5M
- P/E
- 0.0×
Follow BIORQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 38.45 | 26.05 | 205.12 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (1.72) | (2.05) | (21.00) | |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | |
EV/Sales |
— | 99.94 | 72.75 | 272.55 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (1.14) | (1.30) | (5.31) | |
EV/FCF |
— | (1.14) | (1.30) | (5.28) | |
Quick Ratio |
0.25 | 0.23 | 0.13 | 0.03 | |
Current Ratio |
0.30 | 0.28 | 0.20 | 0.05 | |
Net Debt/EBITDA |
(2.39) | (2.56) | (2.63) | (1.09) | |
Debt/Assets |
146.44% | 196.84% | 250.11% | 135.96% | |
Debt/Equity |
(0.45) | (0.45) | (0.51) | (0.18) | |
Asset Turnover |
0.00 | 0.01 | 0.03 | 0.04 | |
Operating CF/Net income |
0.89 | 2.98 | (1.69) | 0.47 | |
Capex/Depreciation |
(0.11) | 0.00 | (0.40) | (0.02) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,292.44% | 2,422.64% | 17,531.25% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,670.30% | 2,641.51% | 33,278.13% | |
Intangible Assets out of Total Assets |
0.19 | 0.26 | 0.33 | 0.42 | |
Share Based Compensation of Revenue |
0.00% | 283.95% | 494.65% | 4,003.13% | |
Graham Net Nets |
— | (5.07) | (4.37) | (0.63) | |
Graham Number |
— | 144.64 | 77.55 | 26.68 | |
Earnings Yield |
— | (369.92%) | (169.67%) | (215.94%) | |
Free Cash Flow Yield |
— | (227.45%) | (215.38%) | (25.19%) | |
Revenue per Share |
0.00 | 0.19 | 0.09 | 0.00 | |
Operating CF per Share |
(8.71) | (4.27) | (3.07) | (0.24) | |
Capex per Share |
(0.04) | 0.00 | (0.05) | 0.00 | |
Free Cash Flow per Share |
(8.76) | (4.26) | (3.12) | (0.24) | |
Cash per Share |
9.64 | 3.69 | 1.49 | 0.09 | |
Shareholders Equity per Share |
(64.30) | (34.20) | (25.01) | (2.92) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(64.30) | (34.20) | (25.01) | (2.92) | |
Free Cash Flow |
(13.81) | (12.49) | (11.13) | (8.75) | |
Working Capital |
(43.90) | (37.03) | (36.79) | (114.56) | |
Capital Expenditures |
(0.07) | 0.01 | (0.18) | (0.02) | |
Net Current Asset Value |
(113.56) | (109.10) | (98.38) | (115.08) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | 0.57 | 0.59 | |
Net Profit Margin |
0.00% | (772.88%) | 2,033.02% | (57,506.25%) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.83 | 0.83 | 0.82 | 0.84 | |
Average Payables |
3.22 | 4.18 | 6.28 | 5.41 | |
Average Assets |
42.37 | 38.12 | 33.97 | 24.60 | |
Average Common Equity |
(101.85) | (102.59) | (105.10) | (112.71) |
Columns are period end dates